# Shandong Suncadia Medicine Co., Ltd. trials: 87 (2026)

ClinicalTrials.gov lists 87 trials with Shandong Suncadia Medicine Co., Ltd. as lead sponsor, 32 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Shandong Suncadia Medicine Co., Ltd.: 87 rows for $5, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/shandong-suncadia-medicine-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 87
- Recruiting or not yet: 32
- Read on: November 19, 2026

## Trials

The 25 newest of 87, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 15, 2026 | NCT07876596 | A Drug-Drug Interaction Study of Rifampicin and Oral HRS-8080 | Shandong Suncadia Medicine Co., Ltd. | Phase 1 | Not yet recruiting | Breast Cancer | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07876596) |
| September 9, 2026 | NCT07808918 | Safety and Pharmacokinetics of HRS-1597 Tablets in Healthy and Obese Participants: A Phase 1 Study | Shandong Suncadia Medicine Co., Ltd. | Phase 1 | Not yet recruiting | Obese and Metabolic Disorders | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07808918) |
| August 17, 2026 | NCT07767513 | Study of Oral HRS-5346 in Adult Patients With Elevated Lipoprotein(a) and High Risk of Cardiovascular Events | Shandong Suncadia Medicine Co., Ltd. | Phase 2 | Recruiting | Lipoprotein Disorder | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07767513) |
| August 7, 2026 | NCT07752069 | Phase I Clinical Study Evaluating the Relative Bioavailability of Different Formulations of HRS-5346 in Healthy Participants | Shandong Suncadia Medicine Co., Ltd. | Phase 1 | Not yet recruiting | Lipoprotein Disorder | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07752069) |
| July 16, 2026 | NCT07708441 | A Trial of HRS-1780 in Participants With Uncontrolled Hypertension or Resistant Hypertension. | Shandong Suncadia Medicine Co., Ltd. | Phase 2/3 | Recruiting | Uncontrolled or Resistant Hypertension | 914 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07708441) |
| July 16, 2026 | NCT07706777 | Clinical Study of HRS-2129 for Acute Gouty Arthritis | Shandong Suncadia Medicine Co., Ltd. | Phase 2 | Recruiting | Acute Gouty Arthritis | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07706777) |
| June 18, 2026 | NCT07656779 | Human Mass Balance Study of \[¹⁴C\]HRS-1893 | Shandong Suncadia Medicine Co., Ltd. | Phase 1 | Not yet recruiting | Cardiomyopathies | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07656779) |
| June 10, 2026 | NCT07639905 | A Clinical Study Comparing the Bioavailability of HRS-2189 Tablets | Shandong Suncadia Medicine Co., Ltd. | Phase 1 | Completed | Malignant Solid Tumor | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07639905) |
| June 4, 2026 | NCT07625774 | Renal Efficacy and Safety of the Novel Oral Small-Molecule GLP-1RA HRS-7535 Evaluated in Participants With Chronic Kidney Disease | Shandong Suncadia Medicine Co., Ltd. | Phase 3 | Not yet recruiting | Chronic Kidney Disease | 3,690 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07625774) |
| May 27, 2026 | NCT07608705 | A Study to Assess the Effect of HRS-1301 on the Pharmacokinetics of Midazolam and Atorvastatin in Healthy Participants | Shandong Suncadia Medicine Co., Ltd. | Phase 1 | Completed | Hyperlipidemias | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07608705) |
| May 22, 2026 | NCT07601087 | A Clinical Study of HRS-7156 in Healthy Participants | Shandong Suncadia Medicine Co., Ltd. | Phase 1 | Recruiting | Heart Failure | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07601087) |
| May 22, 2026 | NCT07601048 | A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment | Shandong Suncadia Medicine Co., Ltd. | Phase 3 | Not yet recruiting | KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07601048) |
| May 15, 2026 | NCT07589569 | An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer | Shandong Suncadia Medicine Co., Ltd. | Phase 2 | Recruiting | Pancreatic Cancer | 92 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07589569) |
| April 29, 2026 | NCT07557407 | A Mass Balance Study of \[14C\]HRS-1780 in Healthy Adult Male Subjects | Shandong Suncadia Medicine Co., Ltd. | Phase 1 | Not yet recruiting | Chronic Kidney Diseases | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07557407) |
| April 14, 2026 | NCT07528027 | Phase III Study of HRS-7535 for Hypertension With Overweight or Obesity | Shandong Suncadia Medicine Co., Ltd. | Phase 3 | Recruiting | Hypertension With Overweight or Obesity | 648 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07528027) |
| March 18, 2026 | NCT07479641 | A Bioequivalence Study of Two Formulations of HRS-1893 Tablets in Healthy Participants | Shandong Suncadia Medicine Co., Ltd. | Phase 1 | Completed | Cardiomyopathy | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07479641) |
| March 13, 2026 | NCT07470983 | A Phase II Clinical Study on the Efficacy and Safety of HRS-1780 in Participants With Primary Aldosteronism | Shandong Suncadia Medicine Co., Ltd. | Phase 2 | Active not recruiting | Primary Aldosteronism | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07470983) |
| February 19, 2026 | NCT07419828 | A Phase III Clinical Study on the Efficacy and Safety of HRS-1780 in the Treatment of Patients With Chronic Kidney Disease | Shandong Suncadia Medicine Co., Ltd. | Phase 3 | Recruiting | Chronic Kidney Disease | 5,386 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07419828) |
| February 5, 2026 | NCT07389733 | A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced... | Shandong Suncadia Medicine Co., Ltd. | Phase 1/2 | Recruiting | Advanced Unresectable or Metastatic Breast Cancer of Adults | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07389733) |
| January 30, 2026 | NCT07377721 | A Study of HRS-2129 in Patients With Diabetic Peripheral Neuropathic Pain | Shandong Suncadia Medicine Co., Ltd. | Phase 1 | Recruiting | Diabetic Peripheral Neuropathic Pain | 168 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07377721) |
| January 21, 2026 | NCT07354022 | A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer... | Shandong Suncadia Medicine Co., Ltd. | Phase 3 | Recruiting | Locally Advanced or Metastatic Breast Cancer | 912 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07354022) |
| January 20, 2026 | NCT07351968 | A Phase Ib Study to Evaluate the Efficacy and Safety of HRS-2129 in Patients With Knee Osteoarthritis | Shandong Suncadia Medicine Co., Ltd. | Phase 1 | Completed | Moderate Pain in Knee Osteoarthritis, Severe Pain in Knee Osteoarthritis | 202 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07351968) |
| January 16, 2026 | NCT07349069 | A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer | Shandong Suncadia Medicine Co., Ltd. | Phase 3 | Recruiting | Breast Cancer | 5,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07349069) |
| January 7, 2026 | NCT07322016 | A Study of HRS-1301 Tablets in Healthy Subjects and Those With Impaired Kidney Function | Shandong Suncadia Medicine Co., Ltd. | Phase 1 | Completed | Hyperlipidemias | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07322016) |
| January 6, 2026 | NCT07320521 | A Study to Assess the Mass Balance of \[14C\]HRS-8080 in Healthy Chinese Postmenopausal Female Subjects. | Shandong Suncadia Medicine Co., Ltd. | Phase 1 | Completed | Breast Cancer | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07320521) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 47 |
| Phase 1/2 | 7 |
| Phase 2 | 20 |
| Phase 2/3 | 2 |
| Phase 3 | 11 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 40 |
| Recruiting | 25 |
| Unknown | 12 |
| Not yet recruiting | 7 |
| Active not recruiting | 3 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Diabetes Mellitus, Type 2 | 14 |
| Breast Neoplasms | 11 |
| Renal Insufficiency, Chronic | 7 |
| Obesity | 7 |
| Cardiomyopathy, Hypertrophic | 6 |
| Hyperlipidemias | 5 |
| Overweight | 4 |
| Cardiomyopathies | 3 |
| Pain | 2 |
| Diabetes Mellitus | 2 |
| Diabetic Nephropathies | 1 |
| Metabolic Diseases | 1 |
| Weight Loss | 1 |
| Neoplasm Metastasis | 1 |
| Pancreatic Neoplasms | 1 |
| Heart Failure | 1 |
| Inflammatory Bowel Diseases | 1 |
| Hyperaldosteronism | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Internet marketing agencies in the United States](https://specstream.ai/data/businesses/internet-marketing-agencies/united-states)
- [Manufacturing consultants in the United States](https://specstream.ai/data/businesses/manufacturing-consultants/united-states)
- [Occupational therapy clinics in the United States](https://specstream.ai/data/businesses/occupational-therapy-clinics/united-states)
- [Plastic injection molders in the United States](https://specstream.ai/data/businesses/plastic-injection-molders/united-states)
- [Rehabilitation centers in the United States](https://specstream.ai/data/businesses/rehabilitation-centers/united-states)
- [Speech therapy clinics in the United States](https://specstream.ai/data/businesses/speech-therapy-clinics/united-states)
